Long lasting anti-angiogenic peptides
Modified anti-angiogenic peptides are disclosed. The modified peptides are capable of forming a peptidase stabilized anti-angiogenic peptide. The modified anti-angiogenic peptides, particularly modified kringle 5 peptides are capable of forming a conjugate with a blood protein. Conjugates are prepared from anti-angiogenic peptides, particularly kringle 5 peptides, by combining the peptide with a reactive functional group with a blood protein. The conjugates may be formed in vivo or ex vivo. The conjugates are administered to patients to provide an anti-angiogenic effect.
1. A conjugate formed by a method comprising covalently coupling a modified kringle 5 peptide with human serum albumin, wherein the modified kringle 5 peptide comprises a kringle 5 peptide and a maleimido group coupled to the kringle 5 peptide, optionally via a linking group;
wherein the kringle 5 peptide is a peptide fragment of amino acid residues 443 to 546 of SEQ ID NO: 1, of between 4 and 104 amino acids, and optionally having an amino acid substitution at Cys 523 ;
wherein the maleimido group and optional linking group is optionally coupled to the kringle 5 peptide by one or more additional amino acids;
wherein the kringle 5 peptide is optionally coupled to an N-terminal protecting group;
wherein the kringle 5 peptide has an α-C-terminal carboxy, an α-C-terminal carboxamide, or an α-C-terminal alkylcarboxamide;
wherein said maleimido group reacts with a thiol group of Cys 34 of said human serum albumin to form a conjugate that has a 1:1 loading of said kringle 5 peptide to said human serum albumin.
2. The conjugate of claim 1 , wherein the kringle 5 peptide is selected from the group consisting of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9.
3. The conjugate of claim 1 , wherein the kringle 5 peptide is selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15 and SEQ ID NO:16.
4. The conjugate of claim 1 , wherein the kringle 5 peptide comprises NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH 2 (SEQ ID NO:17) ; NAc- Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH 2 (SEQ ID NO:18); NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys- Leu-Tyr-Asp-Tyr-Lys-NH 2 (SEQ ID NO:19); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly- Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH 2 (SEQ ID NO:20); or NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-NH 2 (SEQ ID NO:21).
5. The conjugate of claim 1 , wherein the modified kringle 5 peptide is selected from the group consisting of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH 2 (SEQ ID NO:22); (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH 2 (SEQ ID NO:23); (MPA)- Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH 2 (SEQ ID NO :24); NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys- Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH 2 (SEQ ID NO:25); (MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro- Arg-Lys-Leu-Tyr-Asp-Tyr-NH 2 (SEQ ID NO:26); (MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu- Tyr-Asp-Tyr-NH 2 (SEQ ID NO:27); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp- Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(NεMPA)-NH 2 (SEQ ID NO:28); (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro- Arg-Lys-Leu-Tyr-Asp-Tyr-NH 2 (SEQ ID NO:29); (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly- Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH 2 (SEQ ID NO:30); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-(NεMPA)-NH 2 (SEQ ID NO:31);(MPA- AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH 2 (SEQ ID NO:32); (MPA)-Arg- Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH 2 (SEQ ID NO:33); NAc-Arg-Lys-Leu-Tyr- Asp-Tyr-Lys-(Nε-MPA)-NH 2 (SEQ ID NO:34); (MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr- NH 2 (SEQ ID NO:35); (MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH 2 (SEQ ID NO:36); NAc-Pro-Arg-Lys- Leu-Tyr-Asp-Lys-(Nε-MPA)-NH 2 (SEQ ID NO:37); (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp- NH 2 (SEQ ID NO:38); (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH2 (SEQ ID NO:39); NAc-Pro-Arg- Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-AEEA-MPA)-NH 2 (SEQ ID NO:40); and NAc-Pro-Arg-Lys- Leu-Tyr-Asp-Tyr-Lys-(Nε-AEEA n -MPA)-NH 2 (SEQ ID NO:41).
6. A composition comprising the conjugate of claim 1 in association with a physiologically acceptable medium.
7. The conjugate of claim 2 , wherein the kringle 5 peptide is SEQ ID NO: 8.
8. The conjugate of claim 2 , wherein the kringle 5 peptide is SEQ ID NO: 9.
9. The conjugate of claim 3 , wherein the kringle 5 peptide is SEQ ID NO: 15.
10. The conjugate of claim 5 , wherein the modified kringle 5 peptide is (MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH 2 (SEQ ID NO:26).
11. The conjugate of claim 5 , wherein the modified kringle 5 peptide is (MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH 2 (SEQ ID NO:27).
12. The conjugate of claim 5 , wherein the modified kringle 5 peptide is NAc- Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH 2 (SEQ ID NO:25).
13. The conjugate of claim 5 , wherein the modified kringle 5 peptide is (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro- Arg-Lys-Leu-Tyr-Asp-Tyr-NH 2 (SEQ ID NO:29).
14. The conjugate of claim 5 , wherein the modified kringle 5 peptide is (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys- Leu-Tyr-Asp-Tyr-NH 2 (SEQ ID NO:30).
15. The conjugate of claim 5 , wherein the modified kringle 5 peptide is (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH 2 (SEQ ID NO:23).
16. The conjugate of claim 5 , wherein the modified kringle 5 peptide is (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH 2 (SEQ ID NO:24).
17. The conjugate of claim 5 , wherein the modified kringle 5 peptide is NAc- Pro-Arg-Lys-Leu-Tyr-Asp-Lys-(Nε-MPA)-NH 2 (SEQ ID NO:37).
18. The conjugate of claim 5 , wherein the modified kringle 5 peptide is NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH 2 (SEQ ID NO:22).